Tricida, Inc. (NASDAQ:TCDA) Major Shareholder Venrock Healthcare Capital Par Purchases 5,951 Shares

Tricida, Inc. (NASDAQ:TCDAGet Rating) major shareholder Venrock Healthcare Capital Par purchased 5,951 shares of the stock in a transaction that occurred on Thursday, June 16th. The stock was acquired at an average cost of $9.69 per share, with a total value of $57,665.19. Following the completion of the acquisition, the insider now directly owns 6,577,189 shares of the company’s stock, valued at $63,732,961.41. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

  • On Monday, June 13th, Venrock Healthcare Capital Par purchased 50,000 shares of Tricida stock. The stock was acquired at an average cost of $8.14 per share, with a total value of $407,000.00.
  • On Friday, June 10th, Venrock Healthcare Capital Par acquired 58,054 shares of Tricida stock. The stock was purchased at an average price of $8.91 per share, with a total value of $517,261.14.
  • On Wednesday, June 8th, Venrock Healthcare Capital Par acquired 111,111 shares of Tricida stock. The stock was purchased at an average price of $9.51 per share, with a total value of $1,056,665.61.
  • On Monday, June 6th, Venrock Healthcare Capital Par purchased 91,506 shares of Tricida stock. The shares were bought at an average price of $9.35 per share, with a total value of $855,581.10.
  • On Thursday, June 2nd, Venrock Healthcare Capital Par purchased 61,722 shares of Tricida stock. The shares were bought at an average price of $8.78 per share, with a total value of $541,919.16.

Tricida stock traded up $0.73 during trading hours on Tuesday, hitting $11.00. The stock had a trading volume of 864,046 shares, compared to its average volume of 392,446. The company has a debt-to-equity ratio of 584.92, a current ratio of 5.12 and a quick ratio of 5.12. The stock has a market capitalization of $609.68 million, a price-to-earnings ratio of -3.82 and a beta of 0.92. Tricida, Inc. has a 1-year low of $3.55 and a 1-year high of $12.45. The stock’s fifty day moving average is $9.41 and its two-hundred day moving average is $9.11.

Tricida (NASDAQ:TCDAGet Rating) last posted its earnings results on Tuesday, March 29th. The company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.21). During the same quarter in the prior year, the business earned ($1.09) earnings per share. As a group, sell-side analysts anticipate that Tricida, Inc. will post -2.2 EPS for the current year.

Several research analysts have issued reports on TCDA shares. The Goldman Sachs Group cut their price objective on Tricida from $22.00 to $16.00 and set a “buy” rating for the company in a research report on Tuesday, May 24th. Needham & Company LLC reiterated a “buy” rating and issued a $18.00 price objective (down previously from $20.00) on shares of Tricida in a research report on Wednesday, March 30th.

A number of institutional investors have recently bought and sold shares of TCDA. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Tricida by 92.2% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,270 shares of the company’s stock valued at $27,000 after acquiring an additional 1,569 shares during the last quarter. Dorsey Wright & Associates acquired a new stake in shares of Tricida during the first quarter valued at $30,000. BlackRock Inc. boosted its stake in shares of Tricida by 0.5% during the first quarter. BlackRock Inc. now owns 965,743 shares of the company’s stock valued at $7,937,000 after acquiring an additional 4,966 shares during the last quarter. Bank of America Corp DE boosted its stake in shares of Tricida by 290.5% during the first quarter. Bank of America Corp DE now owns 7,400 shares of the company’s stock valued at $61,000 after acquiring an additional 5,505 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new stake in shares of Tricida during the first quarter valued at $45,000. 79.28% of the stock is currently owned by institutional investors.

Tricida Company Profile (Get Rating)

Tricida, Inc operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track.

Further Reading

Insider Buying and Selling by Quarter for Tricida (NASDAQ:TCDA)

Want More Great Investing Ideas?

Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.